Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review
Abstract
:1. Background
2. Nitric Oxide and Lung Fibrosis: Rationale
3. Multiple Flows Feno Assessment: The Technical Approach
4. Extended Feno Analysis in Ilds: Current Evidence
4.1. SSC-ILD
4.2. IPF
4.3. Granulomatous Interstitial Lung Diseases
4.4. Exposure-Related Lung Fibrosis
4.5. Eosinophilic Pneumonia
4.6. The Value of Extended Eno Analysis in Differential Diagnosis of Ild
5. Comorbidities/Complications of Ilds: A Pitfall for Eno Analysis?
5.1. Pulmonary Hypertension
5.2. Obstructive Sleep Apnea
5.3. Emphysema
5.4. Lung Cancer
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Gustafsson, L.E.; Leone, A.M.; Persson, M.G.; Wiklund, N.P.; Moncada, S. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem. Biophys. Res. Commun. 1991, 181, 852–857. [Google Scholar] [CrossRef]
- Singh, S.; Gupta, A.K. Nitric oxide: Role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother. Pharmacol. 2011, 67, 1211–1224. [Google Scholar] [CrossRef] [PubMed]
- Michel, T.; Feron, O. Nitric oxide synthases: Which, where, how, and why? J. Clin. Investig. 1997, 100, 2146–2152. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am. J. Respir. Crit. Care Med. 2005, 171, 912–930. [Google Scholar] [CrossRef] [PubMed]
- Gong, S.; Pu, Y.; Xie, L.; Yang, X.; Mao, H. Fraction of exhaled nitric oxide is elevated in patients with stable chronic obstructive pulmonary disease: A meta-analysis. Am. J. Med. Sci. 2020, 360, 166–175. [Google Scholar] [CrossRef] [PubMed]
- Mostafavi-Pour-Manshadi, S.-M.-Y.; Naderi, N.; Barrecheguren, M.; Dehghan, A.; Bourbeau, J. Investigating fractional exhaled nitric oxide in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): A scoping review. COPD 2018, 15, 377–391. [Google Scholar] [CrossRef]
- Krauss, E.; Froehler, M.; Degen, M.; Mahavadi, P.; Dartsch, R.C.; Korfei, M.; Ruppert, C.; Seeger, W.; Guenther, A. Exhalative breath markers do not offer for diagnosis of interstitial lung diseases: Data from the european IPF registry (eurIPFreg) and Biobank. J. Clin. Med. 2019, 8, 643. [Google Scholar] [CrossRef] [Green Version]
- Cameli, P.; Bargagli, E.; Bergantini, L.; Refini, R.M.; Pieroni, M.; Sestini, P.; Tottoli, P. Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease. J. Breath Res. 2019, 27, 026008. [Google Scholar] [CrossRef]
- Horváth, I.; Barnes, P.J.; Loukides, S.; Sterk, P.J.; Högman, M.; Olin, A.-C.; Amann, A.; Antus, B.; Baraldi, E.; Bikov, A.; et al. A european respiratory society technical standard: Exhaled biomarkers in lung disease. Eur. Respir. J. 2017, 49, 1600965. [Google Scholar] [CrossRef] [Green Version]
- Hosseinzadeh, A.; Javad-Moosavi, S.A.; Reiter, R.J.; Yarahmadi, R.; Ghaznavi, H.; Mehrzadi, S. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis. Exp. Opin. Ther. Targets 2018, 22, 1049–1061. [Google Scholar] [CrossRef]
- Cameli, P.; Carleo, A.; Bergantini, L.; Landi, C.; Prasse, A.; Bargagli, E. Oxidant/antioxidant disequilibrium in idiopathic pulmonary fibrosis pathogenesis. Inflammation 2020, 43, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Raghu, G.; Remy-Jardin, M.; Myers, J.L.; Richeldi, L.; Ryerson, C.J.; Lederer, D.J.; Behr, J.; Cottin, V.; Danoff, S.K.; Morell, F.; et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 2018, 198, e44–e68. [Google Scholar] [CrossRef] [PubMed]
- Sgalla, G.; Iovene, B.; Calvello, M.; Ori, M.; Varone, F.; Richeldi, L. Idiopathic pulmonary fibrosis: Pathogenesis and management. Respir. Res. 2018, 22, 19–32. [Google Scholar] [CrossRef] [PubMed]
- Schwentker, A.; Vodovotz, Y.; Weller, R.; Billiar, T.R. Nitric oxide and wound repair: Role of cytokines? Nitric Oxide 2002, 7, 1–10. [Google Scholar] [CrossRef]
- Gutierrez, H.H.; Pitt, B.R.; Schwarz, M.; Watkins, S.C.; Lowenstein, C.; Caniggia, I.; Chumley, P.; Freeman, B.A. Pulmonary alveolar epithelial inducible No synthase gene expression: Regulation by inflammatory mediators. Am. J. Physiol. 1995. [Google Scholar] [CrossRef]
- Romanska, H.M.; Polak, J.M.; Coleman, R.A.; James, R.S.; Harmer, D.W.; Allen, J.C.; Bishop, A.E. iNOS gene upregulation is associated with the early proliferative response of human lung fibroblasts to cytokine stimulation. J. Pathol. 2002, 197, 372–379. [Google Scholar] [CrossRef]
- Huffman, L.J.; Prugh, D.J.; Millecchia, L.; Schuller, K.C.; Cantrell, S.; Porter, D.W. Nitric oxide production by rat bronchoalveolar macrophages or polymorphonuclear leukocytes following intratracheal instillation of lipopolysaccharide or silica. J. Biosci. 2003, 28, 29–37. [Google Scholar] [CrossRef]
- Iyer, A.K.V.; Ramesh, V.; Castro, C.A.; Kaushik, V.; Kulkarni, Y.M.; Wright, C.A.; Venkatadri, R.; Rojanasakul, Y.; Azad, N. Nitric oxide mediates bleomycin-induced angiogenesis and pulmonary fibrosis via regulation of VEGF. J. Cell Biochem. 2015, 116, 2484–2893. [Google Scholar] [CrossRef] [Green Version]
- Xu, J.; Luo, Y.; Yuan, C.; Han, L.; Wu, Q.; Xu, L.; Gao, Y.; Sun, Y.; Ma, S.; Tang, G.; et al. Downregulation of nitric oxide collaborated with radiotherapy to promote anti-tumor immune response via inducing cd8+ t cell infiltration. Int. J. Biol. Sci. 2020, 16, 1563–1574. [Google Scholar] [CrossRef] [Green Version]
- Jang, A.-S.; Lee, J.-U.; Choi, I.-S.; Park, K.-O.; Lee, J.H.; Park, S.-W.; Cho, K.H.; Hyun, J.H.; Na, Y.G.; Song, K.H.; et al. Expression of nitric oxide synthase, aquaporin 1 and aquaporin 5 in rat after bleomycin inhalation. Intensiv. Care Med. 2004, 30, 489–495. [Google Scholar]
- Pullamsetti, S.S.; Savai, R.; Dumitrascu, R.; Dahal, B.K.; Wilhelm, J.; Konigshoff, M.; Zakrezwicz, D.; Ardeschir Ghofrani, H.; Weissmann, N.; Eickelberg, O.; et al. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci. Transl. Med. 2011. [Google Scholar] [CrossRef] [PubMed]
- Janssen, W.; Pullamsetti, S.S.; Cooke, J.; Weissmann, N.; Guenther, A.; Schermuly, R.T. The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. J. Pathol. 2013, 229, 242–249. [Google Scholar] [CrossRef] [PubMed]
- Kulkarni, Y.M.; Dutta, S.; Iyer, A.K.V.; Venkatadri, R.; Kaushik, V.; Ramesh, V.; Wright, C.A.; Semmes, O.J.; Yakisich, J.S.; Azad, N. A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis. Proteomics 2016, 16, 33–46. [Google Scholar] [CrossRef] [Green Version]
- Sato, S.; Shinohara, S.; Hayashi, S.; Morizumi, S.; Abe, S.; Okazaki, H.; Chen, Y.; Goto, H.; Aono, Y.; Ogawa, H.; et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir. Res. 2017, 18, 172. [Google Scholar] [CrossRef] [PubMed]
- Matucci Cerinic, M.; Kahaleh, M.B. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology 2002, 41, 843–847. [Google Scholar] [CrossRef] [Green Version]
- Hua-Huy, T.; Le-Dong, N.-N.; Duong-Quy, S.; Bei, Y.; Rivière, S.; Tiev, K.-P.; Nicoo, C.; Chereau, C.; Batteux, F.; Dinh-Xuan, A.T. Increased exhaled nitric oxide precedes lung fibrosis in two murine models of systemic sclerosis. J. Breath Res. 2015, 9, 036007. [Google Scholar] [CrossRef] [PubMed]
- Noguchi, S.; Yatera, K.; Wang, K.-Y.; Oda, K.; Akata, K.; Yamasaki, K.; Toshinori, K.; Ishimoto, H.; Toyohira, Y.; Shimokawa, H.; et al. Nitric oxide exerts protective effects against bleomycin-induced pulmonary fibrosis in mice. Respir. Res. 2014, 15, 92. [Google Scholar] [CrossRef] [Green Version]
- George, S.C.; Hogman, M.; Permutt, S.; Silkoff, P.E. Modeling pulmonary nitric oxide exchange. J. Appl. Physiol. 2003, 96, 831–839. [Google Scholar] [CrossRef]
- Condorelli, P.; Shin, H.-W.; Aledia, A.S.; Silkoff, P.E.; George, S.C. A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J. Appl. Physiol. 2007, 102, 417–425. [Google Scholar] [CrossRef]
- Högman, M.; Thornadtsson, A.; Hedenstierna, G.; Meriläinen, P. A practical approach to the theoretical models to calculate NO parameters of the respiratory system. J. Breath Res. 2014, 8, 016002. [Google Scholar] [CrossRef]
- Tsoukias, N.M.; George, S.C. A two-compartment model of pulmonary nitric oxide exchange dynamics. J. Appl. Physiol. 1998, 85, 653–666. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Girgis, R.E.; Gugnani, M.K.; Abrams, J.; Mayes, M.D. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. Am. J. Respir. Crit. Care Med. 2002, 165, 1587–1591. [Google Scholar] [CrossRef] [PubMed]
- Wuttge, D.M.; Bozovic, G.; Hesselstrand, R.; Aronsson, D.; Bjermer, L.; Scheja, A.; Hellmark, T.; Hesselstrand, R.; Tuedsson, L. Increased alveolar nitric oxide in early systemic sclerosis. Clin. Exp. Rheumatol. 2010, 28, S5–S9. [Google Scholar] [PubMed]
- Benfante, A.; Messina, R.; Paternò, A.; Scichilone, N. Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis. Minerva Med. 2018, 109, 71–78. [Google Scholar] [PubMed]
- Hua-Huy, T.; Tiev, K.P.; Chéreau, C.; Duong-Quy, S.; Cabane, J.; Dinh-Xuan, A.T. Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis. J. Rheumatol. 2010, 37, 1680–1687. [Google Scholar] [CrossRef]
- Tiev, K.P.; Coste, J.; Ziani, M.; Aubourg, F.; Cabane, J.; Dinh-Xuan, A.T. Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2009, 26, 32–38. [Google Scholar]
- Tiev, K.P.; Cabane, J.; Aubourg, F.; Kettaneh, A.; Ziani, M.; Mouthon, L.; Duong-Quy, I.; Guillevin, L.; Dinh-Xuan, A.T. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur. Respir. J. 2007, 30, 26–30. [Google Scholar] [CrossRef]
- Tiev, K.P.; Hua-Huy, T.; Kettaneh, A.; Allanore, Y.; Le-Dong, N.-N.; Duong-Quy, S.; Cabane, J.; Dinh-Xuan, A.T. Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma. Thorax 2012, 67, 157–163. [Google Scholar] [CrossRef] [Green Version]
- Tiev, K.P.; Rivière, S.; Hua-Huy, T.; Cabane, J.; Dinh-Xuan, A.T. Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease. Nitric Oxide 2014, 40, 17–21. [Google Scholar] [CrossRef]
- Schildge, J. Nitric oxide in exhaled breath of patients with interstitial lung diseases. Pneumologie 2011, 65, 143–148. [Google Scholar] [CrossRef] [Green Version]
- Zhao, Y.; Cui, A.; Wang, F.; Wang, X.-J.; Chen, X.; Jin, M.-L.; Huang, K.-W. Characteristics of pulmonary inflammation in combined pulmonary fibrosis and emphysema. Chin. Med. J. 2012, 125, 3015–3021. [Google Scholar] [PubMed]
- Cameli, P.; Bargagli, E.; Refini, R.M.; Pieroni, M.G.; Bennett, D.; Rottoli, P. Exhaled nitric oxide in interstitial lung diseases. Respir. Physiol. Neurobiol. 2014, 197, 46–52. [Google Scholar] [CrossRef] [PubMed]
- Cameli, P.; Barbagli, E.; Rottoli, P. Exhaled nitric oxide is not increased in pulmonary sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2016, 33, 39–40. [Google Scholar] [PubMed]
- Kotecha, J.; Shulgina, L.; Sexton, D.W.; Atkins, C.P.; Wilson, A.M. Plasma vascular endothelial growth factor concentration and alveolar nitric oxide as potential predictors of disease progression and mortality in idiopathic pulmonary fibrosis. J. Clin. Med. 2016, 5, 80. [Google Scholar] [CrossRef] [Green Version]
- Cameli, P.; Bergantini, L.; Salvini, M.; Refini, R.M.; Pieroni, M.; Bargagli, E.; Sestini, P. Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis. Nitric Oxide 2019, 89, 41–45. [Google Scholar] [CrossRef] [PubMed]
- Cameli, P.; Bergantini, L.; D’alessandro, M.; Vietri, L.; Refini, R.M.; Pieroni, M.; Sestini, P.; Bargagli, E. Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis. Minerva Med. 2019. [Google Scholar] [CrossRef]
- Moodley, Y.P.; Chetty, R.; Lalloo, U.G. Nitric oxide levels in exhaled air and inducible nitric oxide synthase immunolocalization in pulmonary sarcoidosis. Eur. Respir. J. 1999, 14, 822–827. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choi, J.; Hoffman, L.A.; Sethi, J.M.; Zullo, T.G.; Gibson, K.F. Multiple flow rates measurement of exhaled nitric oxide in patients with sarcoidosis: A pilot feasibility study. Sarcoidosis Vasc. Diffuse Lung Dis. 2009, 26, 98–109. [Google Scholar]
- Terrington, D.L.; Hayton, C.; Peel, A.; Fowler, S.J.; Fraser, W.; Wilson, A.M. The role of measuring exhaled breath biomarkers in sarcoidosis: A systematic review. J. Breath Res. 2019, 24, 036015. [Google Scholar] [CrossRef] [Green Version]
- Shirai, T.; Ikeda, M.; Morita, S.; Asada, K.; Suda, T.; Chida, K. Elevated alveolar nitric oxide concentration after environmental challenge in hypersensitivity pneumonitis. Respirology 2010, 15, 721–722. [Google Scholar] [CrossRef]
- Guilleminault, L.; Saint-Hilaire, A.; Favelle, O.; Caille, A.; Boissinot, E.; Henriet, A.C.; Diot, P.; Marchand-Adam, S. Can exhaled nitric oxide differentiate causes of pulmonary fibrosis? Respir. Med. 2013, 107, 1789–1796. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lehtonen, H.; Oksa, P.; Lehtimäki, L.; Sepponen, A.; Nieminen, R.; Kankaanranta, H.; Saarelainen, S.; Järvenpää, R.; Uitti, J.; Moilanen, E. Increased alveolar nitric oxide concentration and high levels of leukotriene B(4) and 8-isoprostane in exhaled breath condensate in patients with asbestosis. Thorax 2007, 62, 602–607. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sandrini, A.; Johnson, A.R.; Thomas, P.S.; Yates, D.H. Fractional exhaled nitric oxide concentration is increased in asbestosis and pleural plaques. Respirology 2006, 11, 325–329. [Google Scholar] [CrossRef] [PubMed]
- Furukawa, K.; Sugiura, H.; Matsunaga, K.; Ichikawa, T.; Koarai, A.; Hirano, T.; Yanagisawa, S.; Minakata, Y.; Akamatsu, K.; Kanda, M.; et al. Increase of nitrosative stress in patients with eosinophilic pneumonia. Respir. Res. 2011, 12, 81. [Google Scholar] [CrossRef] [Green Version]
- Oishi, K.; Hirano, T.; Suetake, R.; Ohata, S.; Yamaji, Y.; Ito, K.; Edakuni, N.; Matsunaga, K. Exhaled nitric oxide measurements in patients with acute-onset interstitial lung disease. J. Breath Res. 2017, 11, 036001. [Google Scholar] [CrossRef] [Green Version]
- Steen, V.D.; Medsger, T.A. Changes in causes of death in systemic sclerosis, 1972–2002. Ann. Rheum. Dis. 2007, 66, 940–944. [Google Scholar] [CrossRef] [Green Version]
- Elhai, M.; Meune, C.; Boubaya, M.; Avouac, J.; Hachulla, E.; Balbir-Gurman, A.; Riemekasten, G.; Airo, P.; Joven, B.; Vettori, S.; et al. Mapping and predicting mortality from systemic sclerosis. Ann. Rheum. Dis. 2017, 76, 1897–1905. [Google Scholar] [CrossRef]
- Distler, O.; Highland, K.B.; Gahlemann, M.; Azuma, A.; Fischer, A.; Mayes, M.D.; Raghu, G.; Sauter, W.; Girard, M.; Alves, M.; et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 2019, 380, 2518–2528. [Google Scholar] [CrossRef]
- Fajac, I.; Kahan, A.; Menkès, C.J.; Dessanges, J.F.; Dall’Ava-Santucci, J.; Dinh-Xuan, A.T. Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin. Exp. Rheumatol. 1998, 16, 547–552. [Google Scholar]
- Moodley, Y.P.; Lalloo, U.G. Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease. Chest 2001, 119, 1449–1454. [Google Scholar] [CrossRef] [Green Version]
- Kharitonov, S.A.; Cailes, J.B.; Black, C.M.; du Bois, R.M.; Barnes, P.J. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997, 52, 1051–1055. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rolla, G.; Colagrande, P.; Scappaticci, E.; Chiavassa, G.; Dutto, L.; Cannizzo, S.; Cao, Z.; Mathai, S.C.; Hummers, L.K.; Shah, A.A.; et al. Exhaled nitric oxide in systemic sclerosis: Relationships with lung involvement and pulmonary hypertension. J. Rheumatol. 2000, 27, 1693–1698. [Google Scholar] [PubMed]
- Travis, W.D.; Costabel, U.; Hansell, D.M.; King, T.E.; Lynch, D.A.; Nicholson, A.G.; Ryerson, C.J.; Ryu, J.H.; Selman, M.; Wells, A.U.; et al. an official american thoracic society/european respiratory society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013, 188, 733–748. [Google Scholar] [CrossRef] [PubMed]
- D’Alessandro, M.; Bergantini, L.; Cameli, P.; Vietri, L.; Lanzarone, N.; Alonzi, V.; Pieroni, M.; Refini, R.M.; Sestini, P.; Bonella, F.; et al. Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: A comprehensive review. Biomark. Med. 2020, 158, 646–659. [Google Scholar]
- Campo, I.; Zorzetto, M.; Bonella, F. Facts and promises on lung biomarkers in interstitial lung diseases. Exp. Rev. Respir. Med. 2015, 9, 437–457. [Google Scholar] [CrossRef]
- Hoshino, T.; Sakazaki, Y.; Sawada, M.; Oda, H.; Takenaka, S.-I.; Kawayama, T.; Izuhara, K.; Aizawa, H. Periostin, A Matrix Protein, Is A Novel Biomarker For Idiopathic Interstitial Pneumonias With Active Fibrosis. B67. Fibroblast Biol. Nov. Biomark. Microenviron. 2011, 37, 1119–1127. [Google Scholar] [CrossRef]
- Prasse, A.; Pechkovsky, D.V.; Toews, G.B.; Jungraithmayr, W.; Kollert, F.; Goldmann, T.; Vollmer, E.; Müller-Quernheim, J.; Zissel, G. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am. J. Respir. Crit. Care Med. 2006, 173, 781–792. [Google Scholar] [CrossRef] [Green Version]
- Cameli, P.; Bergantini, L.; D’alessandro, M.; Vietri, L.; Cameli, M.; Sestini, P.; Bargagli, E. Serum CD59: A novel biomarker of idiopathic pulmonary fibrosis? Panminerva Med. 2020, 11, 1–8. [Google Scholar]
- Chien, J.W.; Richards, T.J.; Gibson, K.F.; Zhang, Y.; Lindell, K.O.; Shao, L.; Lyman, S.K.; Adamkewicz, J.I.; Smith, V.; Kaminski, N.; et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur. Respir. J. 2014, 43, 1430–1438. [Google Scholar] [CrossRef] [Green Version]
- Saleh, D.; Barnes, P.J.; Giaid, A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1997, 155, 1763–1769. [Google Scholar] [CrossRef]
- Montaldo, C.; Cannas, E.; Ledda, M.; Rosetti, L.; Congiu, L.; Atzori, L. Bronchoalveolar glutathione and nitrite/nitrate in idiopathic pulmonary fibrosis and sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2002, 19, 54–58. [Google Scholar] [PubMed]
- Behera, D.; Kaur, S.; Sathyanarayana, G.; Bhatnagar, A.; Majumdar, S. Nitric oxide derivative in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Indian J. Chest Dis. Allied Sci. 2002, 44, 21–24. [Google Scholar] [PubMed]
- Facchetti, F.; Vermi, W.; Fiorentini, S.; Chilosi, M.; Caruso, A.; Duse, M.; Notarangelo, L.D.; Badolato, R. Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. Am. J. Pathol. 1999, 154, 145–152. [Google Scholar] [CrossRef] [Green Version]
- Ziora, D.; Polońska, A.; Kałuska, K.; Rozentryt, P.; Trzeciak, P. Concentration of nitric oxide in exhaled air in patients with sarcoidosis--pilot study. Pneumonol. Alergol. Pol. 2002, 70, 290–295. [Google Scholar] [PubMed]
- Wilsher, M.; Fergusson, W.; Milne, D.; Wells, A. Exhaled nitric oxide in sarcoidosis. Thorax 2005, 60, 967–970. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ziora, D.; Kaluska, K.; Kozielski, J. An increase in exhaled nitric oxide is not associated with activity in pulmonary sarcoidosis. Eur. Respir. J. 2004, 24, 609–614. [Google Scholar] [CrossRef] [Green Version]
- Ojanguren, I.; Cruz, M.J.; Villar, A.; Barrecheguren, M.; Morell, F.; Muñoz, X. Utility of exhaled nitric oxide fraction for the diagnosis of hypersensitivity pneumonitis. Lung 2016, 194, 75–80. [Google Scholar] [CrossRef]
- Tanaka, S.; Choe, N.; Hemenway, D.R.; Zhu, S.; Matalon, S.; Kagan, E. Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat. J. Clin. Investig. 1998, 102, 445–454. [Google Scholar] [CrossRef]
- Nishiike, T.; Nishimura, Y.; Wada, Y.; Iguchi, H. Production of nitric oxide elevates nitrosothiol formation resulting in decreased glutathione in macrophages exposed to asbestos or asbestos substitutes. Arch. Toxicol. 2005, 79, 83–89. [Google Scholar] [CrossRef]
- Rapisarda, V.; Loreto, C.; Ledda, C.; Musumeci, G.; Bracci, M.; Santarelli, L.; Renis, M.; Ferrante, M.; Cardile, V. Cytotoxicity, oxidative stress and genotoxicity induced by glass fibers on human alveolar epithelial cell line A549. Toxicol. In Vitro 2015, 29, 551–557. [Google Scholar] [CrossRef]
- Franko, A.; Dodič-Fikfak, M.; Arnerić, N.; Dolžan, V. Inducible nitric oxide synthase genetic polymorphism and risk of asbestosis. J. Biomed. Biotechnol. 2011, 2011, 685870. [Google Scholar] [CrossRef] [PubMed]
- Franko, A.; Dolžan, V.; Arnerić, N.; Dodič-Fikfak, M. The influence of gene-gene and gene-environment interactions on the risk of asbestosis. Biomed. Res. Int. 2013, 2013, 405743. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cottin, V. Eosinophilic lung diseases. Clin. Chest Med. 2016, 37, 535–556. [Google Scholar] [CrossRef] [PubMed]
- Pijnenburg, M.W. The role of FeNO in predicting asthma. Front. Pediatr. 2019, 7, 41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harari, S.; Elia, D.; Humbert, M. Pulmonary hypertension in parenchymal lung diseases: Any future for new therapies? Chest 2018, 153, 217–223. [Google Scholar] [CrossRef] [PubMed]
- Lettieri, C.J.; Nathan, S.D.; Barnett, S.D.; Ahmad, S.; Shorr, A.F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006, 129, 746–752. [Google Scholar] [CrossRef]
- Minai, O.A.; Santacruz, J.F.; Alster, J.M.; Budev, M.M.; McCarthy, K. Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir. Med. 2012, 106, 1613–1621. [Google Scholar] [CrossRef] [Green Version]
- Akbay, N.O.; Bingol, Z.; Kiyan, E.; Karaayvaz, E.B.; Bilge, A.K.; Issever, H.; Okumus, G.; Kıyan, E. Fractional exhaled nitric oxide measurement in pulmonary hypertension: A follow-up study. Clin. Appl. Thromb. Hemost. 2018, 24, 483–488. [Google Scholar] [CrossRef]
- Malekmohammad, M.; Folkerts, G.; Kashani, B.S.; Naghan, P.A.; Dastenae, Z.H.; Khoundabi, B.; Garssen, J.; Mortaz, E.; Adcock, I.M. Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy. BMC Pulm. Med. 2019, 19, 188. [Google Scholar] [CrossRef] [Green Version]
- Malerba, M.; Radaeli, A.; Ragnoli, B.; Airo, P.; Corradi, M.; Ponticiello, A.; Zambruni, A.; Grassi, V. Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. Chest 2007, 132, 575–580. [Google Scholar] [CrossRef]
- Carpagnano, G.E.; Radaeli, A.; Lacedonia, D.; Correale, M.; Carpagnano, G.; Palmiotti, A.; Barbaro, M.P.F.; Di, B.M.; Brunetti, N.D.; Scioscia, G.; et al. Exhaled nitric oxide and exhaled breath temperature as potential biomarkers in patients with pulmonary hypertension. Biomed. Res. Int. 2018, 2018, 7292045. [Google Scholar] [CrossRef] [PubMed]
- Cao, Z.; Mathai, S.C.; Hummers, L.K.; Shah, A.A.; Wigley, F.M.; Lechtzin, N.; Hassoun, P.M.; Girgis, R.E. Exhaled nitric oxide in pulmonary arterial hypertension associated with systemic sclerosis. Pulm. Circ. 2016, 6, 545–550. [Google Scholar] [CrossRef] [PubMed]
- Kozij, N.K.; Granton, J.T.; Silkoff, P.E.; Thenganatt, J.; Chakravorty, S.; Johnson, S.R. Exhaled nitric oxide in systemic sclerosis lung disease. Can. Respir. J. 2017, 2017, 6736239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fortuna, A.M.; Miralda, R.; Calaf, N.; González, M.; Casan, P.; Mayos, M. Airway and alveolar nitric oxide measurements in obstructive sleep apnea syndrome. Respir. Med. 2011, 105, 630–636. [Google Scholar] [CrossRef] [Green Version]
- Zhang, D.; Xiao, Y.; Luo, J.; Wang, X.; Qiao, Y.; Huang, R.; Wu, W. Measurement of fractional exhaled nitric oxide and nasal nitric oxide in male patients with obstructive sleep apnea. Sleep Breath 2019, 23, 785–793. [Google Scholar] [CrossRef] [Green Version]
- Carpagnano, G.E.; Spanevello, A.; Sabato, R.; Depalo, A.; Turchiarelli, V.; Foschino Barbaro, M.P. Exhaled pH, exhaled nitric oxide, and induced sputum cellularity in obese patients with obstructive sleep apnea syndrome. Transl. Res. 2008, 151, 45–50. [Google Scholar] [CrossRef]
- Chua, A.-P.; Aboussouan, L.S.; Minai, O.A.; Paschke, K.; Laskowski, D.; Dweik, R.A. Long-term continuous positive airway pressure therapy normalizes high exhaled nitric oxide levels in obstructive sleep apnea. J. Clin. Sleep Med. 2013, 9, 529–535. [Google Scholar] [CrossRef]
- Liu, J.; Li, Z.; Liu, Z.; Zhu, F.; Li, W.; Jiang, H.; Wu, X.; Song, Y.; Li, S.; Bai, C. Exhaled nitric oxide from the central airway and alveoli in OSAHS patients: The potential correlations and clinical implications. Sleep Breath 2016, 20, 145–154. [Google Scholar] [CrossRef]
- Mavroudi, M.; Papakosta, D.; Kontakiotis, T.; Domvri, K.; Kalamaras, G.; Zarogoulidou, V.; Zarogoulidis, P.; Latka, P.; Huang, H.; Hohenforst-Schmidt, W. Sleep disorders and health-related quality of life in patients with interstitial lung disease. Sleep Breath 2018, 22, 393–400. [Google Scholar] [CrossRef]
- Lancaster, L.H.; Mason, W.R.; Parnell, J.A.; Rice, T.W.; Loyd, J.E.; Milstone, A.P.; Collard, H.R.; Malow, B.A. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009, 136, 772–778. [Google Scholar] [CrossRef] [Green Version]
- Bosi, M.; Milioli, G.; Fanfulla, F.; Tomassetti, S.; Ryu, J.H.; Parrino, L.; Riccardi, S.; Melpignano, A.; Vaudano, A.E.; Ravaglia, C.; et al. OSA and prolonged oxygen desaturation during sleep are strong predictors of poor outcome in ipf. Lung 2017, 195, 643–651. [Google Scholar] [CrossRef]
- Cottin, V.; Nunes, H.; Brillet, P.-Y.; Delaval, P.; Devouassoux, G.; Tillie-Leblond, I.; Israel-Biet, M.; Court-Fortune, I.; Valeyre, D.; Cordier, J.-F. Combined pulmonary fibrosis and emphysema: A distinct underrecognised entity. Eur. Respir. J. 2005, 26, 586–593. [Google Scholar] [CrossRef] [PubMed]
- Cottin, V.; Le Pavec, J.; Prévot, G.; Mal, H.; Humbert, M.; Simonneau, G.; Cordier, J.-F. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur. Respir. J. 2010, 35, 105–111. [Google Scholar] [CrossRef]
- Kawahara, T.; Sakashita, H.; Suzuki, T.; Tateishi, T.; Miyazaki, Y. Real world data of combined lung cancer and interstitial lung disease. J. Thorac. Dis. 2019, 11, 4144–41451. [Google Scholar] [CrossRef] [PubMed]
- Choi, W.-I.; Park, S.H.; Park, B.J.; Lee, C.W. Interstitial lung disease and lung cancer development: A 5-year nationwide population-based study. Cancer Res. Treat. 2018, 50, 374–381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Whittaker Brown, S.-A.; Padilla, M.; Mhango, G.; Powell, C.; Salvatore, M.; Henschke, C.; Yankelevitz, D.; Sigel, K.; De-Torres, J.P.; Wisnivesky, J. Interstitial lung abnormalities and lung cancer risk in the national lung screening trial. Chest 2019, 156, 1195–1203. [Google Scholar] [CrossRef] [PubMed]
- Raghu, G.; Nyberg, F.; Morgan, G. The epidemiology of interstitial lung disease and its association with lung cancer. Br. J. Cancer 2004, 91, S3–S10. [Google Scholar] [CrossRef]
- Liu, P.-F.; Zhao, D.-H.; Qi, Y.; Wang, J.-G.; Zhao, M.; Xiao, K.; Xie, L. The clinical value of exhaled nitric oxide in patients with lung cancer. Clin. Respir. J. 2018, 12, 23–30. [Google Scholar] [CrossRef]
Author (Year) | Study Type | Sample Size | Principal Results | Ref |
---|---|---|---|---|
SSC-ILD Girgis et al. (2002) | Observational, cross-sectional study |
|
| [32] |
Wuttge et al. (2010) | Observational, cross-sectional study |
|
| [33] |
Benfante et al. (2018) | Observational, cross-sectional study |
|
| [34] |
Hua-Huy et al. (2010) | Observational, cross-sectional study |
|
| [35] |
Tiev et al. (2009) | Observational, cross-sectional study |
|
| [36] |
Tiev et al. (2007) | Observational, cross-sectional study |
|
| [37] |
Tiev et al. (2012) | Observational, 3-y longitudinal study |
|
| [38] |
Tiev et al. (2014) | Open-label, monocentric uncontrolled trial |
|
| [39] |
IPF Cameli et al. (2019) | Observational, retrospective study |
|
| [8] |
Schildge (2011) | Observational, cross sectional study |
|
| [40] |
Zhao et al. (2012) | Observational, cross sectional study |
|
| [41] |
Cameli et al. (2014) | Observational, cross-sectional study |
|
| [42] |
Cameli et al. (2016) | Observational, retrospective study |
|
| [43] |
Kotecha et al. (2016) | Observational, prospective study |
|
| [44] |
Cameli et al. (2019) | Observational, retrospective study |
|
| [45] |
Cameli et al. (2019) | Observational, retrospective study |
|
| [46] |
Granulomatous ILDs Moodley et al. (1999) | Open-label, monocentric study |
|
| [47] |
Choi et al. (2009) | Observational, cross-sectional study |
|
| [48] |
Terrington et al. (2019) | Systematic review and meta-analysis |
|
| [49] |
Shirai et al. (2010) | Case report |
|
| [50] |
Guilleminault et al. (2013) | Observational, cross-sectional study |
|
| [51] |
Exposure-related ILDs Lehtonen et al. (2007) | Observational, cross sectional study |
|
| [52] |
Sandrini et al. (2006) | Observational, cross-sectional study |
|
| [53] |
Eosinophilic pneumonia Furukawa et al. (2011) | Open-label, monocentric uncontrolled study |
|
| [54] |
Oishi et al. (2017) | Observational, cross sectional study |
|
| [55] |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cameli, P.; Bargagli, E.; Bergantini, L.; d’Alessandro, M.; Pieroni, M.; Fontana, G.A.; Sestini, P.; Refini, R.M. Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review. Int. J. Mol. Sci. 2020, 21, 6187. https://doi.org/10.3390/ijms21176187
Cameli P, Bargagli E, Bergantini L, d’Alessandro M, Pieroni M, Fontana GA, Sestini P, Refini RM. Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review. International Journal of Molecular Sciences. 2020; 21(17):6187. https://doi.org/10.3390/ijms21176187
Chicago/Turabian StyleCameli, Paolo, Elena Bargagli, Laura Bergantini, Miriana d’Alessandro, Maria Pieroni, Giovanni A. Fontana, Piersante Sestini, and Rosa Metella Refini. 2020. "Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review" International Journal of Molecular Sciences 21, no. 17: 6187. https://doi.org/10.3390/ijms21176187